A Conversation With Massimo Cristofanilli, MD, FACP
By Jo Cavallo
September 15, 2014, Volume 5, Issue 15
Tests in development to detect circulating tumor cells that escape from solid tumors and travel through the blood, spreading cancer to new sites, may serve as an alternative to conventional tissue biopsy for early cancer diagnosis and gene-expression analysis over the next decade. According to Massimo Cristofanilli, MD, FACP, Director of the Jefferson Breast Care Center and Deputy Director of Translational Research at the Kimmel Cancer Center at Thomas Jefferson University and Hospitals in Philadelphia, blood tests called “liquid biopsies” will provide oncologists with more accurate information of the cancer’s biology, its aggressiveness, and whether treatment is working than information currently gleaned from tissue biopsy analysis.